Dual-domain peptide for depleting HMGB1 from the circulation via liver HSPG system

The dual-domain peptide hE-HMGB1-BP and associated inhibitors target HMGB1 and GSNOR pathways to address SCD-induced vasculopathy and lung disease, improving vasodilation and lung function by reducing HMGB1 levels and inhibiting inflammatory and oxidative stress mechanisms.

WO2024238337A1PCT designated stage expired Publication Date: 2024-11-21MEDICAL COLLEGE OF WISCONSIN INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028808
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-02
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Sickle cell disease (SCD) causes vasculopathy and chronic lung disease through mechanisms involving high mobility group box-1 (HMGB1) and S-nitrosoglutathione reductase (GSNOR), which impair vasodilation and increase chronic lung injury by reducing nitric oxide bioavailability.

Method used

A dual-domain peptide, hE-HMGB1-BP, is designed to bind and deplete HMGB1 from circulation via the liver's heparin sulfate proteoglycan system, and N-acetyl-lysyltyrosylcysteine amide (KYC) is used to inhibit myeloperoxidase-initiated and HMGB1-propagated inflammatory pathways, while N6022 inhibits GSNOR to restore vasodilation and improve lung morphometries.

Benefits of technology

The approach effectively reduces HMGB1 levels, improves endothelial and eNOS-dependent vasodilation, decreases liver injury, and enhances lung protein S-nitrosylation, thereby alleviating SCD-induced vasculopathy and chronic lung injury by targeting HMGB1 and GSNOR pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000047
    Figure 000047
  • Figure 000048
    Figure 000048
  • Figure 000049
    Figure 000049
Patent Text Reader

Abstract

An end-capped (N-acetylated, C-amidated) dual-domain peptide called hE-HMGBl-BP was designed to bind and deplete HMGB1 from circulation via uptake by the liver's heparin sulfate proteoglycan (HSPG) system.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Peptide-Based Peroxidase Inhibitors and Methods of Using Same

    US20140194342A1

  • Apoe mimetic peptides and higher potency to clear plasma cholesterol

    US20170209537A1